IXICO to Present at Alzheimer's Disease Congress

RNS Number : 2147V

IXICO plc

02 December 2019

 

2^nd December 2019                                                                                                                                         

IXICO plc

("IXICO" or the "Company")

IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer's Disease Congress

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience clinical drug development, today announces that it is scheduled to attend and present scientific posters at the 2019 Clinical Trials on Alzheimer's Disease (CTAD) Congress held from 4^th-7^th December 2019 in San Diego, California, USA.

CTAD Congress 2019

4^th - 7^th December 2019, Hilton Bayfront, San Diego, USA

IXICO will present three posters during break-out sessions in the Indigo Foyer on Thursday, 5^th December.  Details of the posters are as follows:

"Classifying cognitively healthy subjects from mild cognitive impaired and Alzheimer's disease patients using Tau-PET: the role of spatial resolution and PET pre-processing"

Given the connection between Alzheimer's disease and the spatial bio-distribution of misfolded phosphorylated Tau protein, this research investigates how the uptake of Tau-PET scans differs in patients affected with different degrees of cognitive impairment. 

Poster authors:

Richard Joules¹, Alessandro Palombit¹, Richard Manber¹, Richard Parker¹, Robin Wolz^1,2

Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College London, UK

 "A fully automatic pipeline for estimation of regional brain volume change using Jacobian Integration"

The poster highlights the methods used for estimating regional brain volume change in Alzheimer's disease patients, by validating the fully automatic Jacobian Integration pipeline using LEAP technology against the commonly accepted standard Boundary Shift Integration (BSI) method when estimating volume change in the lateral ventricles of an Alzheimer's disease cohort.

Poster authors:

Richard Joules¹, Robin Wolz^1,2, Richard Parker¹

Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College London, UK

"A pipeline for automated diffusion MRI analysis: overview and application to the study of Alzheimer's disease"

This research introduces and validates a pipeline for the analysis of diffusion MRI brain scan data that is fully integrated into IXICO's trial management software, TrialTracker™: a web-based tool for data upload, storage, data analysis and quality assessment of processed data. The pipeline is applied to a cohort of older adults with and without Alzheimer's disease.

Poster authors:

Richard Joules¹, Robin Wolz^1,2, Richard Parker¹

Affiliations: 1- IXICO Plc, London, UK, 2- Imperial College London, UK

Alison Howie, Chief Product Officer of IXICO, commented: "We are delighted to be presenting three abstracts at this year's CTAD Congress, demonstrating IXICO's expertise in advancing data analytics to deliver intelligent insights which are vital in ensuring the successful progression of clinical trials. IXICO's key mission is the development of data analytics to speed the advancement of effective treatments for neurodegenerative diseases, like Alzheimer's disease, that tragically affect so many patients worldwide."

For further information please contact:

IXICO plc	[phone]
Alison Howie, Chief Product Officer
Optimum Strategic Communications	[phone]
Mary Clark / Supriya Mathur / Manel Mateus
[e-mail]

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease. 

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

About CTAD Congress 2019

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide but presents huge challenges. The goal of the meeting is to bring together today's worldwide leaders in the treatment of Alzheimer's disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments. 

Clinical trial teams from worldwide centres report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk from Alzheimer's disease, to predict progression, and assess the effectiveness of new treatments. https://www.ctad-alzheimer.com/

 

END

 

 

NRAMMMZMVLVGLZM